- GlucoTrack (GCTK) announced that Mark Tapsak, Ph.D. has joined the company as Vice President of Sensor Technology, effective immediately
- Mark brings over 25 years of experience in the diabetes industry as a medical device research scientist
- CEO Paul Goode sat down with Daniella Atkinson to discuss Dr. Tapsak’s hiring and the impact he’ll have on the company
- GlucoTrack is focused on the design, development, and commercialization of non-invasive glucose monitoring technologies
- GlucoTrack, Inc. (GCTK) opened trading at US$1.90
GlucoTrack (GCTK) has hired Dr. Mark Tapsak, Ph.D., as Vice President of Sensor Technology, effective immediately.
Mark brings over 25 years of experience in the diabetes industry as a medical device research scientist focused on polymer synthesis, polymer characterization, medical device design and intellectual property. At GlucoTrack, he will lead the recently announced R&D program for a novel implantable continuous glucose monitoring system (CGM) for those with Type 1 diabetes.
CEO Paul Goode sat down with Daniella Atkinson to discuss Dr. Tapsak’s hiring and the impact he’ll have on the company.
“Mark and I worked together in the early days of development at DexCom, and I am thrilled to be working with him again. By bringing together a veteran team with proficiency in the implantable device and glucose sensing space, we are looking to bring life-changing products to market that are designed to prioritize both health and comfort, enabling freedom from the pain and inconvenience currently plaguing patients with diabetes.”
GlucoTrack is focused on the design, development, and commercialization of non-invasive glucose monitoring technologies for people with diabetes and prediabetes.
GlucoTrack, Inc. (GCTK) opened trading at US$1.90.